Home

Discover ArthroSave

Are you a patient with painful knee osteoarthritis below the age of 65 years? Return to your active life after a six weeks treatment with the KneeReviver.

What

The KneeReviver unloads the damaged knee joint by putting the knee joint surfaces on a short distance. With this temporary unloading treatment the knee joint tissues regenerate.

For whom

Patients diagnosed with knee osteoarthritis, not responding to conservative therapy, probably already indicated for a knee replacement, under the age of 65 years old.

Results

This unloading treatment is studied in medical research groups for > 10 years, resulting in knee joint preservation, decrease of pain, increase of function, and postponing a knee replacement.

Postponing the need for total knee replacement,

avoiding complex revision surgery

The KneeReviver

  • Consists of 2 tubes placed on both sides of the knee
  • Is fixated to the bone by eight bone pins
  • Unloads the knee joint by creating space between the joint surfaces
  • It is allowed to bear weight during treatment, however it is not possible to bend the knee

The Knee Reviver is developed by ArthroSave, in collaboration with orthopaedic surgeons, researchers and patients. It is the only device with intended use for knee joint distraction.

Knee joint distraction is a joint preserving

surgical treatment with use of the KneeReviver

News

First patients treated in KARDS study with the KneeReviver

In Leeds Teaching Hospital two patients were successfully treated with the KneeReviver for a knee joint preserving surgery as start of the KARDS study. ArthroSave has trained orthopaedic surgeons and the theatre staff to use the KneeReviver system. The patients are suffering from severe knee osteoarthritis being too young for a total knee replacement.

The patients were treated on 22 July 2021 in the KARDS study to keep longer their own knee joint while postponing the placement of a first knee replacement. ArthroSave partners with STERIS IMS a provider of reprocessing services facilitating safe and reliable sterile ready delivery of the KneeReviver to the KARDS participating hospitals in the United Kingdom.

Leeds Teaching Hospital is the leader of the KARDS study; Knee ARthroplasty vs Distraction Study (KARDS) is a pragmatic, two-arm NI multi-centre trial designed to establish the clinical & cost-effectiveness of knee joint distraction in a NHS setting. In total 344 patients will be included in two years.

Surgical joint distraction without alignment correction for knee osteoarthritis has gained momentum as an option to delay knee replacement. NICE guidance in this area has found the evidence around this intervention to be lacking in quality and quantity and so has sponsored the KARDS study for further research into this procedure that should lead to future reimbursement. In total 20 hospitals in the United Kingdom are participating in the KARDS study.

Clinical Trial Knee Distraction funded by Zorginstituut Nederland

With a grant of € 6.7 million from the National Health Care Institute (Zorginstituut Nederland), 14 orthopedic departments of Dutch hospitals are conducting research under the supervision of UMC Utrecht into the (cost) effectiveness of knee distraction. Knee distraction is a promising new joint preserving treatment for patients under the age of 65 with end-stage knee osteoarthritis postponing the total knee replacement for years.

Current clinical research and the recent review of this by the National Health Care Institute showed that treatment with knee distraction for patients younger than 65 years of age is a promising intervention, but at present insufficiently substantiated to be part of reimbursed care. Without reimbursement, such promising treatment for a large population of patients dies a silent death. “With the grant we can now conduct thorough research and demonstrate that the application of knee distraction for the designated target group is really good care,” said study leader, epidemiologist and health technology assessment researcher at UMC Utrecht Paco Welsing.

This is very good news as this means that in 2022-2024 in the Netherlands 600 patients with severe knee osteoarthritis under the age of 65 will be treated with knee distraction and preserving their own knee. We are pleased ArthroSave is fully involved in this study.

For more information (in Dutch):